Company news
Adagene, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
October 28, 2026
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
October 27, 2026
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
April 2, 2026
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
December 16, 2025
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
October 31, 2025
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
September 16, 2025
Decks
- Investor Presentation (September 2026)
Investor deck · 34 slides · September 2026
- Investor Presentation (July 2023)
Investor deck · 31 slides · Jul 7, 2023
- Investor Presentation (January 2022)
Investor deck · 19 slides · Jan 12, 2022